Janux Therapeutics Inc (JANX) Price & Analysis

Compare

603 Followers

JANX Stock Chart & Stats

$13.79

-$2.71(-4.69%)

At close: Jan 08 4:00 PM EST

$13.79

-$2.71(-4.69%)

Day’s Range― - ―

52-Week Range$13.76 - $61.59

Previous CloseN/A

Volume1.13M

Average Volume (3M)2.43M

Market Cap

$829.44M

Enterprise Value$549.53M

Total Cash (Recent Filing)$988.99M

Total Debt (Recent Filing)$22.66M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Mar 06, 2026

EPS Estimate

-0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding60,147,808

10 Day Avg. Volume2,928,301

30 Day Avg. Volume2,433,920

Financial Highlights & Ratios

PEG Ratio13.76

Price to Book (P/B)2.81

Price to Sales (P/S)271.80

P/FCF Ratio-65.15

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue54.95

Enterprise Value/Gross Profit57.85

Enterprise Value/Ebitda-4.19

Forecast

1Y Price Target

$56.42

Price Target Upside309.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

EPS Forecast (FY)-1.95

Revenue Forecast (FY)$10.06M

Bulls Say, Bears Say

Bulls Say

Drug EfficacyJANX007 is a viable drug with a reasonable safety profile and the potential to show a benefit in OS over Pluvicto, especially in the taxane-naïve mCRPC setting.

Financial OutlookThe analyst maintains a Buy rating on JANX and a 12-month price target of $70, based on a risk-adjusted net present value analysis of projected future revenues.

Market PositionJanux is potentially in the lead position with masked T cell engaging (TCE) assets.

Bears Say

Competitive LandscapeThe taxane-naive setting is highly competitive, with anticipated increased competition from other TCEs and small-molecule candidates.

Stock PerformanceJanux shares are trading down more than 40% after hours in response to the data release, which is believed to be an overreaction.

Trial Design UncertaintyUncertainty remains on the pivotal trial design and timeline for JANX.

Janux Therapeutics Inc News

Janux Therapeutics price target lowered to $29 from $48 at Barclays

Barclays lowered the firm’s price target on Janux Therapeutics (JANX) to $29 from $48 and keeps an Overweight...

6d ago

JANX

Midday Fly By; Kalshi hits $11B valuation, MongoDB reports Q3 beat

The major averages were broadly higher near noon, indicating some stabilization after yesterday’s pullback. Some of the gains...

21d ago

Janux Therapeutics falls -48.4%

Janux Therapeutics (JANX) is down -48.4%, or -$16.46 to $17.52. Published first on TheFly – the ultimate source...

21d ago

JANX

Janux Therapeutics falls -49.4%

Janux Therapeutics (JANX) is down -49.4%, or -$16.78 to $17.21. Published first on TheFly – the ultimate source...

21d ago

JANX

Janux Therapeutics price target lowered to $150 from $200 at Cantor Fitzgerald

Cantor Fitzgerald analyst Josh Schimmer lowered the firm’s price target on Janux Therapeutics (JANX) to $150 from $200...

21d ago

JANX

Janux Therapeutics price target lowered to $38 from $46 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Janux Therapeutics (JANX) to $38 from $46 and...

21d ago

JANX

Why Is Janux Therapeutics Stock (JANX) Crashing today?

Janux Therapeutics ($JANX) stock plunged 40% in Tuesday’s pre-market trading after the clinical-stage biopharmaceutical company announced “positive” interim...

21d ago

JANX

Janux Therapeutics price target lowered to $49 from $58 at BofA

BofA lowered the firm’s price target on Janux Therapeutics (JANX) to $49 from $58 and keeps a Buy...

21d ago

JANX

Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Janux Therapeutics (JANX) to $45 from $70 and keeps a...

21d ago

JANX

Janux Therapeutics price target lowered to $32 from $80 at Clear Street

Clear Street lowered the firm’s price target on Janux Therapeutics (JANX) to $32 from $80 and keeps a...

21d ago

JANX

Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise

After five consecutive winning days for U.S. indices, the first trading session of December got off to a...

22d ago

MDB

WMT

Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential

JonesTrading analyst Soumit Roy has reiterated their bullish stance on JANX stock, giving a Buy rating today. Soumit...

21d ago

JANX

Buy Rating Reaffirmed for JANX007 Amid Promising Survival Metrics and Competitive Positioning

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Janux...

21d ago

JANX

Buy Rating Affirmed for JANX007 Amid Promising Phase 1 Data and Market Dislocation

Janux Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Justin Zelin...

21d ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $13.76 and its highest was $61.59 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $829.44M.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is Mar 06, 2026 which is in 73 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.62.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 60,147,808 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.606%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Janux Therapeutics Inc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-12.48%

Trailing 12-Months

Asset Growth

47.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics Inc (JANX) is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company utilizes its proprietary platform technology to create a new class of therapeutics designed to selectively activate the immune system against tumors. Janux specializes in the development of its product candidates that aim to enhance the body's ability to fight cancer while minimizing adverse effects on healthy tissues. The company is advancing several candidates through preclinical and clinical stages, targeting various types of cancers.

Janux Therapeutics Inc (JANX) Earnings & Revenues

Historic Earnings Reports

JANX Stock 12 Month Forecast

Average Price Target

$56.42

▲(309.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","86":"$86","151":"$151","53.5":"$53.5","118.5":"$118.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,53.5,86,118.5,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,42.91384615384615,51.83769230769231,60.761538461538464,69.6853846153846,78.60923076923078,87.53307692307692,96.45692307692306,105.38076923076923,114.30461538461537,123.22846153846154,132.1523076923077,141.07615384615383,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,35.715384615384615,37.440769230769234,39.16615384615385,40.89153846153846,42.61692307692308,44.34230769230769,46.06769230769231,47.793076923076924,49.51846153846154,51.24384615384616,52.96923076923077,54.69461538461539,{"y":56.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,33.29846153846154,32.60692307692308,31.915384615384617,31.223846153846154,30.532307692307693,29.840769230769233,29.14923076923077,28.45769230769231,27.76615384615385,27.074615384615385,26.383076923076924,25.691538461538464,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >